Copaxone 40mg Generic: FDA Exceeds Mylan's Expectations
Executive Summary
FDA approves the product well before Mylan's prediction of 2018.
You may also be interested in...
Complex ANDAs: Early Meetings With FDA Can Generate Bonus Communication
By conducting a product development or pre-submission meeting, sponsors can receive a mid-review cycle meeting for a complex product ANDA.
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Company says that while FDA has focused on expediting approval of third and fourth generics, it has not done so for first generics and complex products.
FDA's Off-Patent, Off-Exclusivity List Draws Few Takers Early On
US agency has received 'very few' inquiries about the drugs on the list since its release.